Animal Testing

Debate between Chi Onwurah and Tracey Crouch

Monday 19th February 2024 Westminster Hall

[Tracey Crouch]

For the record, I do not advocate or support any testing on dogs, particularly in the manner that the hon. Lady described. My point was that some past research on animals has enabled a great many positive outcomes for cancer patients, such as myself.

[Chi Onwurah]

I thank the hon. Member for her intervention. I was not implying support for a specific type of testing, but making a general point: some have argued in the past that animal testing has been necessary to save human lives, and groups such as Understanding Animal Research argue that currently. Understanding Animal Research also gives the example of Duchenne muscular dystrophy, a lethal childhood disease, as a condition where canine models are effective.

Science and innovation can show the way out of this moral maze. To take the example of testing on dogs, NC3Rs, the UK’s National Centre for the Replacement, Refinement and Reduction of Animals in Research, has established a project to develop a virtual second species—a virtual dog—using historical data. On toxicity testing, the UK-based company XCellR8 has developed the AcutoX test as a humane alternative to the LD50 test, which involves giving increasing doses of toxic substances to groups of animals until 50% of them are killed.

Just this month, Newcells Biotech, a spinout from Newcastle University based in my constituency, raised over £2 million from the North East Fund for its models of the retina, kidney and lung, which are used in drug development and which reduce reliance on animal testing. The chief executive officer, Dr Mike Nicholds, told me:

“Over the last 10 years, advances in stem cell biology, 3-D bioprinting and high-content analytical methods such as transcriptomics have revolutionised our ability to build laboratory mimics of human tissues that can reduce the use of animals in the early stages of drug discovery. Pioneered in academia, these approaches are now established in mainstream biotech and importantly the regulators have moved to increasingly accept these non-animal models as reliable. Innovations such as retinal organoids, produced by Newcells Biotech, are being used globally to support the development of drugs that cure blindness, demonstrating the power of these new alternatives.”

He went on to say:

“While the prospect of fully replacing animal testing is likely to be at least a decade away, that prospect is no longer beyond the horizon and certainly significant reductions in animal testing will be driven through innovation and awareness within this timescale.”